ARTICLE | Clinical News
APC 366: Started a Phase I trial
January 31, 1994 8:00 AM UTC
Arris Pharmaceutical Corp. (ARRS), South San Francisco Product: APC 366, small molecule that blocks mast cell-mediated inflammation Indication: Asthma Status: Started a Phase I trial ...